Overview

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy

Status:
Completed

Trial end date:
2019-02-03

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) in treating hepatitis C virus (HCV) infection in pediatric participants who are undergoing cancer chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Ledipasvir
Ledipasvir, sofosbuvir drug combination
Sofosbuvir